Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Anticonvulsant vs Placebo Alcohol Withdrawal Seizures post treatment ‐ Any Anticonvulsant vs. Placebo · patients with alcohol withdrawal Anticonvulsants for alcohol withdrawal (2010) · Cochrane | RR 0.61 [0.31, 1.2] | 9 studies · 883 participants | Moderate |
Anticonvulsant vs Placebo Alcohol Withdrawal Seizures post treatment ‐ Phenytoin vs. Placebo · patients with alcohol withdrawal Anticonvulsants for alcohol withdrawal (2010) · Cochrane | RR 0.78 [0.35, 1.77] | 4 studies · 381 participants | Moderate |
Anticonvulsant vs Placebo Adverse events · patients with alcohol withdrawal Anticonvulsants for alcohol withdrawal (2010) · Cochrane | RR 1.56 [0.74, 3.31] | 7 studies · 663 participants | Moderate |
Anticonvulsant vs Placebo Dropout ‐ Any Anticonvulsant vs. Placebo · patients with alcohol withdrawal Anticonvulsants for alcohol withdrawal (2010) · Cochrane | RR 0.82 [0.5, 1.34] | 7 studies · 344 participants | Moderate |
Anticonvulsant vs Placebo Dropout ‐ Chlormethiazole vs. Placebo · patients with alcohol withdrawal Anticonvulsants for alcohol withdrawal (2010) · Cochrane | RR 1.05 [0.22, 5.11] | 3 studies · 140 participants | Moderate |
Anticonvulsant vs Other Drugs Alcohol withdrawal seizures ‐ Any Anticonvulsant vs any Other · patients with alcohol withdrawal Anticonvulsants for alcohol withdrawal (2010) · Cochrane | RR 0.58 [0.22, 1.58] | 12 studies · 880 participants | Low |
Anticonvulsant vs Other Drugs Adverse events ‐ Any Anticonvulsant vs any Other · patients with alcohol withdrawal Anticonvulsants for alcohol withdrawal (2010) · Cochrane | RR 0.71 [0.45, 1.12] | 14 studies · 726 participants | Moderate |
Anticonvulsant vs Other Drugs Dropout ‐ Any Anticonvulsant vs any Other · patients with alcohol withdrawal Anticonvulsants for alcohol withdrawal (2010) · Cochrane | RR 0.92 [0.67, 1.26] | 20 studies · 1359 participants | Moderate |
IL‐10 vs placebo Complete remission (CDAI<150 with a decrease in CDAI of at least 100 points from baseline) · patients with induction of remission in Crohn's disease Recombinant human interleukin 10 for induction of remission in Crohn's disease (2010) · Cochrane | RR 1.43 [0.62, 3.29] | 3 studies · 470 participants | Moderate |
IL‐10 vs placebo Clinical remision (CDAI<150) · patients with induction of remission in Crohn's disease Recombinant human interleukin 10 for induction of remission in Crohn's disease (2010) · Cochrane | RR 1.29 [0.79, 2.11] | 3 studies · 470 participants | Moderate |
IL‐10 vs placebo Withdrawls due to adverse events · patients with induction of remission in Crohn's disease Recombinant human interleukin 10 for induction of remission in Crohn's disease (2010) · Cochrane | RR 13.5 [3.89, 46.79] | 2 studies · 228 participants | Moderate |
Direct thrombin inhibitors vs low molecular weight heparins Major VTE events bilateral ascending venography1 · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 0.91 [0.69, 1.19] | 11 studies · 17428 participants | Low |
Direct thrombin inhibitors vs low molecular weight heparins All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 2.06 [1.1, 3.87] | 11 studies · 22065 participants | Moderate |
Direct thrombin inhibitors vs low molecular weight heparins Total Bleeding events · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 1.17 [0.98, 1.41] | 11 studies · 22109 participants | Low |
Direct thrombin inhibitors vs low molecular weight heparins ALT >3 times the upper normal limit · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 0.41 [0.23, 0.72] | 7 studies · 12580 participants | Low |
Direct thrombin inhibitors vs vitamin K antagonists Major VTE events in TKR combined doses bilateral ascending venography · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 0.85 [0.63, 1.15] | 3 studies · 4327 participants | Low |
Direct thrombin inhibitors vs vitamin K antagonists All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 1.62 [0.57, 4.58] | 3 studies · 5243 participants | Low |
Direct thrombin inhibitors vs vitamin K antagonists Total Bleeding events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 1.26 [0.97, 1.62] | 3 studies · 5259 participants | Low |
Direct thrombin inhibitors vs vitamin K antagonists ALT >3 times the upper normal limit at the end of · patients with prevention of venous thromboembolism following total hip or knee replacement Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of… (2010) · Cochrane | OR 5.61 [1, 31.64] | 2 studies · 4267 participants | Low |
Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty Pain The Hospital for Special Surgrery 100‐point scoring system. Scale from: 0 to 30 (higher is better). · Patients with rheumatoid shoulder Surgical interventions for the rheumatoid shoulder (2010) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty Function The Hospital for Special Surgery 100‐point scoring system. Scale from: 0 to 20 (higher is better). · Patients with rheumatoid shoulder Surgical interventions for the rheumatoid shoulder (2010) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty Quality of life ‐ not reported · Patients with rheumatoid shoulder Surgical interventions for the rheumatoid shoulder (2010) · Cochrane | no estimate extracted | NR | No studies |
Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty Range of motion The Hospital for Special Surgery 100‐point scoring system . Scale from: 0 to 25 (higher is better). · Patients with rheumatoid shoulder Surgical interventions for the rheumatoid shoulder (2010) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty Infections · Patients with rheumatoid shoulder Surgical interventions for the rheumatoid shoulder (2010) · Cochrane | OR 0.13 [0, 6.48] | 1 study · 39 participants | Low |
Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty Component loosening / revisions ‐ not reported · Patients with rheumatoid shoulder Surgical interventions for the rheumatoid shoulder (2010) · Cochrane | no estimate extracted | NR | No studies |
Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty Other complications ‐ not reported · Patients with rheumatoid shoulder Surgical interventions for the rheumatoid shoulder (2010) · Cochrane | no estimate extracted | NR | No studies |
Soft catheters vs Firm catheters Live birth rate · women undergoing intrauterine insemination Soft versus firm catheters for intrauterine insemination (2010) · Cochrane | OR 0.94 [0.65, 1.35] | 3 studies · 896 participants | Low |
Soft catheters vs Firm catheters Pregnancy rate · women undergoing intrauterine insemination Soft versus firm catheters for intrauterine insemination (2010) · Cochrane | OR 1 [0.73, 1.35] | 6 studies · 1210 participants | Very low |
Soft catheters vs Firm catheters Instrumental assistance needed · women undergoing intrauterine insemination Soft versus firm catheters for intrauterine insemination (2010) · Cochrane | no estimate extracted | 2 studies · 986 participants | Ungraded |
Soft catheters vs Firm catheters Blood on catheter tip · women undergoing intrauterine insemination Soft versus firm catheters for intrauterine insemination (2010) · Cochrane | no estimate extracted | 2 studies · 852 participants | Ungraded |
Soft catheters vs Firm catheters Uterine cramping · women undergoing intrauterine insemination Soft versus firm catheters for intrauterine insemination (2010) · Cochrane | no estimate extracted | 2 studies · 290 participants | Ungraded |
Soft catheters vs Firm catheters Miscarriage per woman · women undergoing intrauterine insemination Soft versus firm catheters for intrauterine insemination (2010) · Cochrane | OR 1.25 [0.49, 3.22] | 2 studies · 645 participants | Very low |
GHB 50mg vs placebo be used withdrawal score ‐ 7 hours · patients with alcohol withdrawal Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | no estimate extracted | 1 study · 23 participants | Very low |
GHB 50mg vs GHB 100 mg be used side‐effects ‐ side‐effects causing abandon · patients with alcohol withdrawal Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 0.32 [0.01, 7.66] | 1 study · 65 participants | Low |
GHB 50mg vs placebo be used abstinence ‐ 6 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 1.33 [0.58, 3.07] | 1 study · 17 participants | Low |
GHB 50mg vs placebo be used relapse to heavy drinking ‐ 6 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 0.44 [0.05, 4.02] | 1 study · 17 participants | Low |
GHB 50mg vs placebo be used craving score ‐ 3 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | no estimate extracted | 1 study · 71 participants | Low |
GHB 50mg vs NTX be used abstinence ‐ 12 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 1.34 [0.83, 2.16] | 1 study · 55 participants | Very low |
GHB 50mg vs NTX be used relapses to heavy drinking ‐ 12 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 0.55 [0.18, 1.67] | 1 study · 55 participants | Very low |
GHB 50mg vs NTX be used Alcohol Craving Scale ‐ 12 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
GHB 50mg vs NTX be used side‐effects ‐ side‐effects causing abandon · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 0.62 [0.18, 2.1] | 3 studies · 127 participants | Moderate |
GHB 50mg vs disulfiram be used abstinence ‐ 12 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 1.66 [0.99, 2.8] | 1 study · 59 participants | Very low |
GHB 50mg vs disulfiram be used relapses to heavy drinking ‐ 12 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 1.48 [0.36, 6.03] | 1 study · 59 participants | Very low |
GHB 50mg vs placebo be used side‐effects ‐ tolerated side‐effects · patients with alcohol withdrawal Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 16.25 [1.04, 254.98] | 1 study · 23 participants | Low |
GHB 50mg vs disulfiram be used Alcohol Craving Scale ‐ 12 months · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | no estimate extracted | 1 study · 41 participants | Very low |
GHB 50mg vs disulfiram be used side‐effects ‐ side‐effects causing abandon · alcohol dependent patients Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 0.55 [0.11, 2.79] | 1 study · 59 participants | Very low |
GHB 50mg vs diazepam be used CIWA‐Ar score ‐ day 5 · patients with alcohol withdrawal Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | no estimate extracted | 1 study · 48 participants | Very low |
GHB 50mg vs clomethiazole be used points withdrawal scale ‐ 7 hours · patients with alcohol withdrawal Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | no estimate extracted | 1 study · 21 participants | Very low |
GHB 50mg vs clomethiazole be used CIWA‐Ar score ‐ day 8 · patients with alcohol withdrawal Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | no estimate extracted | 1 study · 59 participants | Low |
GHB 50mg vs clomethiazole be used side‐effects ‐ side‐effects causing abandon · patients with alcohol withdrawal Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (2010) · Cochrane | RR 0.33 [0.01, 7.9] | 1 study · 66 participants | Low |